Sciclone Pharmaceuticals, Inc. (Nasdaq: SCLN) announced its anticipated year-end 2013 cash position and provided its initial 2014 revenue guidance as ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE